⌘K
Loading ticker…
As of 2026-08-24, Inhibrx Biosciences, Inc. Common Stock (INBX) has a 3-month relative strength percentile of 55 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 74. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.9%, relative volume 1.58×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
INBX is in a stage 2 uptrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 14.4% / 20.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
INBX is held by 17 ETFs as of May 2026. Top owner: VTWO at 0.03% weight, $5M notional. Top 3 carry $9M.
Held by 40 ETFs · $118M across latest filings · largest weight 1.20% (BBC).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.03% | $5M | — |
| VFMO | 0.16% | $3M | +0.02 pp |
| CANC | 0.60% | $1M | new |
| VTWV | 0.06% | $738K | +0.01 pp |
| GSSC | 0.07% | $661K | new |
| ONEQ | 0.00% | $510K | — |
| AFSM | 0.16% | $159K | +0.04 pp |
| IBBQ | 0.12% | $81K | +0.04 pp |
| VTHRVanguard Russell 3000 ETF | 0.00% | $71K | — |
| BIB | 0.08% | $56K | +0.02 pp |
Showing 10 of 17 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | INBX Jan avg: -3.10% median: -1.03% win: 50% σ: 6.25% n: 4 2022-04-12 → 2026-07-31 | INBX Feb avg: -3.48% median: -3.28% win: 0% σ: 1.12% n: 4 2022-04-12 → 2026-07-31 | INBX Mar avg: -7.46% median: -6.93% win: 25% σ: 11.27% n: 4 2022-04-12 → 2026-07-31 | INBX Apr avg: 13.88% median: -2.63% win: 40% σ: 45.26% n: 5 2022-04-12 → 2026-07-31 | INBX May avg: -13.48% median: -17.54% win: 40% σ: 26.25% n: 5 2022-04-12 → 2026-07-31 | INBX Jun avg: -3.84% median: -8.90% win: 40% σ: 10.87% n: 5 2022-04-12 → 2026-07-31 | INBX Jul avg: 14.52% median: 2.40% win: 60% σ: 36.43% n: 5 2022-04-12 → 2026-07-31 | INBX Aug avg: 9.51% median: 4.52% win: 100% σ: 13.04% n: 4 2022-04-12 → 2026-07-31 (current) | INBX Sep avg: 3.48% median: 4.37% win: 75% σ: 14.03% n: 4 2022-04-12 → 2026-07-31 | INBX Oct avg: 52.10% median: 40.82% win: 75% σ: 72.97% n: 4 2022-04-12 → 2026-07-31 | INBX Nov avg: 6.41% median: -0.90% win: 50% σ: 19.05% n: 4 2022-04-12 → 2026-07-31 | INBX Dec avg: 14.99% median: -2.58% win: 50% σ: 45.96% n: 4 2022-04-12 → 2026-07-31 |